<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:georss="http://www.georss.org/georss" xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" xmlns:media="http://search.yahoo.com/mrss/"
	>

<channel>
	<title>THE &#34;NEW&#34;  PROSTATE CANCER INFOLINK</title>
	<atom:link href="http://prostatecancerinfolink.net/feed/" rel="self" type="application/rss+xml" />
	<link>http://prostatecancerinfolink.net</link>
	<description></description>
	<lastBuildDate>Sat, 25 May 2013 01:03:54 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.com/</generator>
<cloud domain='prostatecancerinfolink.net' port='80' path='/?rsscloud=notify' registerProcedure='' protocol='http-post' />
<image>
		<url>http://s2.wp.com/i/buttonw-com.png</url>
		<title>THE &#34;NEW&#34;  PROSTATE CANCER INFOLINK</title>
		<link>http://prostatecancerinfolink.net</link>
	</image>
	<atom:link rel="search" type="application/opensearchdescription+xml" href="http://prostatecancerinfolink.net/osd.xml" title="THE &#34;NEW&#34;  PROSTATE CANCER INFOLINK" />
	<atom:link rel='hub' href='http://prostatecancerinfolink.net/?pushpress=hub'/>
		<item>
		<title>&#8220;Raising the bar&#8221; for outcomes after radical prostatectomy</title>
		<link>http://prostatecancerinfolink.net/2013/05/24/raising-the-bar-for-outcomes-after-radical-prostatectomy/</link>
		<comments>http://prostatecancerinfolink.net/2013/05/24/raising-the-bar-for-outcomes-after-radical-prostatectomy/#comments</comments>
		<pubDate>Fri, 24 May 2013 19:32:05 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[outcome]]></category>
		<category><![CDATA[quality]]></category>
		<category><![CDATA[radical prostatectomy]]></category>
		<category><![CDATA[surgery]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=18073</guid>
		<description><![CDATA[There is another rather entertaining, 10-minute video today on the Medscape Oncology web site showing a conversation  between Dr. Matt Cooperberg of the University of California, San Francisco and Dr. Andrew Vickers of the Memorial Sloan-Kettering Cancer Center in New York. The topic of their discussion is what needs to happen to &#8220;raise the bar&#8221; [&#8230;]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=18073&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2013/05/24/raising-the-bar-for-outcomes-after-radical-prostatectomy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/682f740e1805396aa57cefaa6609284f?s=96&#38;d=http%3A%2F%2F0.gravatar.com%2Favatar%2Fad516503a11cd5ca435acc9bb6523536%3Fs%3D96" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Baseline data from the control arm of the STAMPEDE trial</title>
		<link>http://prostatecancerinfolink.net/2013/05/24/baseline-data-from-the-control-arm-of-the-stampede-trial/</link>
		<comments>http://prostatecancerinfolink.net/2013/05/24/baseline-data-from-the-control-arm-of-the-stampede-trial/#comments</comments>
		<pubDate>Fri, 24 May 2013 18:49:13 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[metastatic]]></category>
		<category><![CDATA[outcome]]></category>
		<category><![CDATA[STAMPEDE]]></category>
		<category><![CDATA[survival]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=18071</guid>
		<description><![CDATA[One of the more interesting sets of data on metastatic prostate cancer to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago this year will be some of the very earliest data from the STAMPEDE trial, which we have discussed in some detail in an earlier post. Between [&#8230;]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=18071&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2013/05/24/baseline-data-from-the-control-arm-of-the-stampede-trial/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/682f740e1805396aa57cefaa6609284f?s=96&#38;d=http%3A%2F%2F0.gravatar.com%2Favatar%2Fad516503a11cd5ca435acc9bb6523536%3Fs%3D96" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Vasectomy and risk for prostate cancer all over again</title>
		<link>http://prostatecancerinfolink.net/2013/05/24/vasectomy-and-risk-for-prostate-cancer-all-over-again/</link>
		<comments>http://prostatecancerinfolink.net/2013/05/24/vasectomy-and-risk-for-prostate-cancer-all-over-again/#comments</comments>
		<pubDate>Fri, 24 May 2013 17:17:32 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Diagnosis]]></category>
		<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Risk]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[vasectomy]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=18069</guid>
		<description><![CDATA[Over the years there has been controversy as to the existence of an association between vasectomy and risk for prostate cancer. A new set of data from a large, long-term study, to be presented at the upcoming annual meeting of the American Society of Clinical Oncology, has shown that there is, indeed, such a risk [&#8230;]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=18069&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2013/05/24/vasectomy-and-risk-for-prostate-cancer-all-over-again/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/682f740e1805396aa57cefaa6609284f?s=96&#38;d=http%3A%2F%2F0.gravatar.com%2Favatar%2Fad516503a11cd5ca435acc9bb6523536%3Fs%3D96" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Life expectancy ≤ 10 years and the risks associated with treatment</title>
		<link>http://prostatecancerinfolink.net/2013/05/24/life-expectancy-%e2%89%a4-10-years-and-the-risks-associated-with-treatment/</link>
		<comments>http://prostatecancerinfolink.net/2013/05/24/life-expectancy-%e2%89%a4-10-years-and-the-risks-associated-with-treatment/#comments</comments>
		<pubDate>Fri, 24 May 2013 15:25:22 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Diagnosis]]></category>
		<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Risk]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[active surveillance]]></category>
		<category><![CDATA[age]]></category>
		<category><![CDATA[expectancy]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[monitoring]]></category>
		<category><![CDATA[mortality]]></category>
		<category><![CDATA[risk]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=18050</guid>
		<description><![CDATA[According to Reuters, a new article, forthcoming on line in the Annals of Internal Medicine, tells us (not too surprisingly) that, &#8220;Older men with other illnesses may not live long enough to benefit from aggressive prostate cancer treatments, such as prostate removal or radiation, and they&#8217;d have to live with their side effects.&#8221; Apparently, in [&#8230;]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=18050&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2013/05/24/life-expectancy-%e2%89%a4-10-years-and-the-risks-associated-with-treatment/feed/</wfw:commentRss>
		<slash:comments>5</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/682f740e1805396aa57cefaa6609284f?s=96&#38;d=http%3A%2F%2F0.gravatar.com%2Favatar%2Fad516503a11cd5ca435acc9bb6523536%3Fs%3D96" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Prostate Cancer Roundtable comments on plethora of guidelines on screening</title>
		<link>http://prostatecancerinfolink.net/2013/05/23/prostate-cancer-roundtable-comments-on-plethora-of-guidelines-on-screening/</link>
		<comments>http://prostatecancerinfolink.net/2013/05/23/prostate-cancer-roundtable-comments-on-plethora-of-guidelines-on-screening/#comments</comments>
		<pubDate>Fri, 24 May 2013 00:32:36 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Diagnosis]]></category>
		<category><![CDATA[Risk]]></category>
		<category><![CDATA[guidance]]></category>
		<category><![CDATA[PSA]]></category>
		<category><![CDATA[screening]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=18061</guid>
		<description><![CDATA[As many readers will be aware, there have been two new sets of guidance about screening for prostate cancer issued in the past few months &#8212; the most recent from the American Urological Association just a couple of weeks ago. In response to the fact that we now have a total of four different sets of [&#8230;]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=18061&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2013/05/23/prostate-cancer-roundtable-comments-on-plethora-of-guidelines-on-screening/feed/</wfw:commentRss>
		<slash:comments>4</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/682f740e1805396aa57cefaa6609284f?s=96&#38;d=http%3A%2F%2F0.gravatar.com%2Favatar%2Fad516503a11cd5ca435acc9bb6523536%3Fs%3D96" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Expert opinion on ADT for CRPC today</title>
		<link>http://prostatecancerinfolink.net/2013/05/23/expert-opinion-on-adt-for-crpc-today/</link>
		<comments>http://prostatecancerinfolink.net/2013/05/23/expert-opinion-on-adt-for-crpc-today/#comments</comments>
		<pubDate>Thu, 23 May 2013 19:53:11 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[ADT]]></category>
		<category><![CDATA[androgen]]></category>
		<category><![CDATA[castration-resistant]]></category>
		<category><![CDATA[CRPC]]></category>
		<category><![CDATA[deprivation]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=18059</guid>
		<description><![CDATA[As regular readers will be well aware, the implementation of varying types of androgen deprivation therapy (ADT) in hormone-sensitive and in castration-resistant forms of progressive prostate cancer is evolving. Five or so years from now we may be looking at a very different set of ways to use ADT than those we have been used [&#8230;]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=18059&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2013/05/23/expert-opinion-on-adt-for-crpc-today/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/682f740e1805396aa57cefaa6609284f?s=96&#38;d=http%3A%2F%2F0.gravatar.com%2Favatar%2Fad516503a11cd5ca435acc9bb6523536%3Fs%3D96" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Can we really re-frame low-risk prostate cancer as a chronic disease?</title>
		<link>http://prostatecancerinfolink.net/2013/05/23/can-we-really-re-frame-low-risk-prostate-cancer-as-a-chronic-disease/</link>
		<comments>http://prostatecancerinfolink.net/2013/05/23/can-we-really-re-frame-low-risk-prostate-cancer-as-a-chronic-disease/#comments</comments>
		<pubDate>Thu, 23 May 2013 18:51:39 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Diagnosis]]></category>
		<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Risk]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[chronic]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[outcome]]></category>
		<category><![CDATA[PCOS]]></category>
		<category><![CDATA[risk]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=18055</guid>
		<description><![CDATA[Many readers of this web site may be interested in a video discussion on the Medscape web site between two relatively young urologists about the implications of the Prostate Outcomes Outcomes Study (PCOS), on which we commented a few months back. The discussion between Dr. Daskivich and Dr. Resnick (one of the PCOS investigators) does [&#8230;]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=18055&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2013/05/23/can-we-really-re-frame-low-risk-prostate-cancer-as-a-chronic-disease/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/682f740e1805396aa57cefaa6609284f?s=96&#38;d=http%3A%2F%2F0.gravatar.com%2Favatar%2Fad516503a11cd5ca435acc9bb6523536%3Fs%3D96" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Possible &#8220;pee on a stick&#8221; test for prostate cancer?</title>
		<link>http://prostatecancerinfolink.net/2013/05/22/possible-pee-on-a-stick-test-for-prostate-cancer/</link>
		<comments>http://prostatecancerinfolink.net/2013/05/22/possible-pee-on-a-stick-test-for-prostate-cancer/#comments</comments>
		<pubDate>Wed, 22 May 2013 20:55:00 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Diagnosis]]></category>
		<category><![CDATA[Risk]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=18052</guid>
		<description><![CDATA[According to a story from Southern California Public Radio, a team of researchers at the University of California Irvine are hoping to develop a &#8220;pee on a stick&#8221; test for prostate cancer (like the tests women can use to tell if they are pregnant) based on the ability to detect prostate-specific membrane antigen (PSMA). If [&#8230;]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=18052&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2013/05/22/possible-pee-on-a-stick-test-for-prostate-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/682f740e1805396aa57cefaa6609284f?s=96&#38;d=http%3A%2F%2F0.gravatar.com%2Favatar%2Fad516503a11cd5ca435acc9bb6523536%3Fs%3D96" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>BRCA1/2, prostate cancer, and the Angelina Jolie effect</title>
		<link>http://prostatecancerinfolink.net/2013/05/20/brca12-prostate-cancer-and-the-angelina-jolie-effect/</link>
		<comments>http://prostatecancerinfolink.net/2013/05/20/brca12-prostate-cancer-and-the-angelina-jolie-effect/#comments</comments>
		<pubDate>Mon, 20 May 2013 19:10:44 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Diagnosis]]></category>
		<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[BRCA1]]></category>
		<category><![CDATA[BRCA2]]></category>
		<category><![CDATA[prophylactic]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[surgery]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=18048</guid>
		<description><![CDATA[According to an article in The Sunday Times in the UK over the weekend, a well-known surgeon in the UK is claiming to have carried out &#8220;the first&#8221; radical prostatectomy on a man with no other indicator for treatment except a BRCA2 mutation and a significant family history of breast and prostate cancer. Whether this [&#8230;]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=18048&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2013/05/20/brca12-prostate-cancer-and-the-angelina-jolie-effect/feed/</wfw:commentRss>
		<slash:comments>3</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/682f740e1805396aa57cefaa6609284f?s=96&#38;d=http%3A%2F%2F0.gravatar.com%2Favatar%2Fad516503a11cd5ca435acc9bb6523536%3Fs%3D96" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Surgical responsibility and robot-assisted laparoscopic surgery</title>
		<link>http://prostatecancerinfolink.net/2013/05/20/surgical-responsibility-and-robot-assisted-laparoscopic-surgery/</link>
		<comments>http://prostatecancerinfolink.net/2013/05/20/surgical-responsibility-and-robot-assisted-laparoscopic-surgery/#comments</comments>
		<pubDate>Mon, 20 May 2013 12:14:25 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Diagnosis]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Risk]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[da Vinci]]></category>
		<category><![CDATA[responsibility]]></category>
		<category><![CDATA[robot]]></category>
		<category><![CDATA[trust]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=18043</guid>
		<description><![CDATA[There is an interesting editorial just published on line in the Journal of Urology and written by Prof. Joseph Smith of Vanderbilt University. Unfortunately, because it is an editorial, there is no abstract, and the text is only accessible if you are a subscriber to the journal. As regular readers will be aware, there has [&#8230;]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=18043&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2013/05/20/surgical-responsibility-and-robot-assisted-laparoscopic-surgery/feed/</wfw:commentRss>
		<slash:comments>8</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/682f740e1805396aa57cefaa6609284f?s=96&#38;d=http%3A%2F%2F0.gravatar.com%2Favatar%2Fad516503a11cd5ca435acc9bb6523536%3Fs%3D96" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>First-line enzalutamide in high-risk, ADT-naive patients (including those with metastatic disease)</title>
		<link>http://prostatecancerinfolink.net/2013/05/17/first-line-enzalutamide-in-high-risk-adt-naive-patients-including-those-with-metastatic-disease/</link>
		<comments>http://prostatecancerinfolink.net/2013/05/17/first-line-enzalutamide-in-high-risk-adt-naive-patients-including-those-with-metastatic-disease/#comments</comments>
		<pubDate>Fri, 17 May 2013 14:50:36 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Drugs in development]]></category>
		<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA["high risk"]]></category>
		<category><![CDATA[ADT]]></category>
		<category><![CDATA[enzalutamide]]></category>
		<category><![CDATA[first line]]></category>
		<category><![CDATA[outcome]]></category>
		<category><![CDATA[PSA]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=18040</guid>
		<description><![CDATA[According to data to be presented at the upcoming meeting of the American Society of Clinical Oncology (ASCO), enzalutamide monotherapy substantially reduces PSA levels in androgen deprivation therapy (ADT)-naive patients with progressive or high-risk disease (including men with evident metastases). The data to be presented by Smith et al. are from an open-label, Phase II, [&#8230;]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=18040&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2013/05/17/first-line-enzalutamide-in-high-risk-adt-naive-patients-including-those-with-metastatic-disease/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/682f740e1805396aa57cefaa6609284f?s=96&#38;d=http%3A%2F%2F0.gravatar.com%2Favatar%2Fad516503a11cd5ca435acc9bb6523536%3Fs%3D96" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>ASCO 2013 abstracts now available on line</title>
		<link>http://prostatecancerinfolink.net/2013/05/16/asco-2013-abstracts-now-available-on-line/</link>
		<comments>http://prostatecancerinfolink.net/2013/05/16/asco-2013-abstracts-now-available-on-line/#comments</comments>
		<pubDate>Thu, 16 May 2013 20:30:36 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=18037</guid>
		<description><![CDATA[For readers who want to start hunting through the abstracts of the upcoming annual meeting of the American Society of Clinical Oncology (starting May 31 in Chicago), you can now click here to start looking through all the available information. Filed under: Uncategorized<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=18037&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2013/05/16/asco-2013-abstracts-now-available-on-line/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/682f740e1805396aa57cefaa6609284f?s=96&#38;d=http%3A%2F%2F0.gravatar.com%2Favatar%2Fad516503a11cd5ca435acc9bb6523536%3Fs%3D96" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Olaparib shows activity in advanced, BRCA1/2-positive prostate cancer</title>
		<link>http://prostatecancerinfolink.net/2013/05/16/olaparib-shows-activity-in-advanced-brca12-positive-prostate-cancer/</link>
		<comments>http://prostatecancerinfolink.net/2013/05/16/olaparib-shows-activity-in-advanced-brca12-positive-prostate-cancer/#comments</comments>
		<pubDate>Thu, 16 May 2013 20:26:08 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Drugs in development]]></category>
		<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[activity]]></category>
		<category><![CDATA[BRCA1]]></category>
		<category><![CDATA[BRCA2]]></category>
		<category><![CDATA[olaparib]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=18035</guid>
		<description><![CDATA[Apparently a drug known as olaparib (a so-called poly-ADP ribose polymerase or PARP inhibitor) has shown significant signs of activity against advanced prostate cancer in men who carry the BRCA1 and BRCA2 genes. Olaparib was being tested in an open-label, Phase II trial on BRCA1/2 patients with several different types of cancer including (for the [&#8230;]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=18035&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2013/05/16/olaparib-shows-activity-in-advanced-brca12-positive-prostate-cancer/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/682f740e1805396aa57cefaa6609284f?s=96&#38;d=http%3A%2F%2F0.gravatar.com%2Favatar%2Fad516503a11cd5ca435acc9bb6523536%3Fs%3D96" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Tokai gets funding to expand Phase II trial of galeterone in CRPC</title>
		<link>http://prostatecancerinfolink.net/2013/05/16/tokai-gets-funding-to-expand-phase-ii-trial-of-galeterone-in-crpc/</link>
		<comments>http://prostatecancerinfolink.net/2013/05/16/tokai-gets-funding-to-expand-phase-ii-trial-of-galeterone-in-crpc/#comments</comments>
		<pubDate>Thu, 16 May 2013 13:28:35 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Drugs in development]]></category>
		<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[castration-resistant]]></category>
		<category><![CDATA[CRPC]]></category>
		<category><![CDATA[galeterone]]></category>
		<category><![CDATA[TOK-001]]></category>
		<category><![CDATA[trial]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=18033</guid>
		<description><![CDATA[In April 2012 we had noted that Tokai Pharmaceuticals was planning to initiate a Phase II trial of its investigational drug galeterone (also known as TOK-001) in the treatment of men with castration-resistant prostate cancer (CRPC). The company has now announced that it has the funding to expand enrollment in this Phase II trial. The [&#8230;]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=18033&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2013/05/16/tokai-gets-funding-to-expand-phase-ii-trial-of-galeterone-in-crpc/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/682f740e1805396aa57cefaa6609284f?s=96&#38;d=http%3A%2F%2F0.gravatar.com%2Favatar%2Fad516503a11cd5ca435acc9bb6523536%3Fs%3D96" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>US FDA approves radium-223 dichloride for treatment of men with mCRPC</title>
		<link>http://prostatecancerinfolink.net/2013/05/16/us-fda-approves-radium-223-dichloride-for-treatment-of-men-with-mcrpc/</link>
		<comments>http://prostatecancerinfolink.net/2013/05/16/us-fda-approves-radium-223-dichloride-for-treatment-of-men-with-mcrpc/#comments</comments>
		<pubDate>Thu, 16 May 2013 11:47:28 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[castration-resistant]]></category>
		<category><![CDATA[mCRPC]]></category>
		<category><![CDATA[metastatic]]></category>
		<category><![CDATA[radium-223]]></category>
		<category><![CDATA[Xofigo]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=18030</guid>
		<description><![CDATA[The &#8220;New&#8221; Prostate Cancer InfoLink apologizes for a delay in letting readers know that on Wednesday the US Food &#38; Drug Administration approved radium-223 dichloride (Xofigo®) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, but no known visceral (i.e., soft tissue) metastases. The results of the Phase III clinical trial of [&#8230;]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&#038;blog=3176292&#038;post=18030&#038;subd=talkaboutprostatecancer&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2013/05/16/us-fda-approves-radium-223-dichloride-for-treatment-of-men-with-mcrpc/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/682f740e1805396aa57cefaa6609284f?s=96&#38;d=http%3A%2F%2F0.gravatar.com%2Favatar%2Fad516503a11cd5ca435acc9bb6523536%3Fs%3D96" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
	</channel>
</rss>
